Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. (2nd January 2021)

• Record Type: Journal Article
• Authors: Svensson, Johanna; Lissbrant, Ingela Franck; Gauffin, Oskar; Hjälm-Eriksson, Marie; Kilany, Suzanne; Fagerlund, Karin; Stattin, Pär
• Is Part Of: Scandinavian journal of urology. Volume 55:Number 1(2021)
• Page Start: 1
• Page End: 8
• Publication Date: 2021-01-02
• Subjects: Castration-resistant prostate cancer -- disease state -- healthcare resource utilization -- hormone-sensitive prostate cancer -- metastatic -- non-metastatic -- progression -- registry -- Swedish registry; Urology -- Periodicals; 616.6
• DOI: 10.1080/21681805.2020.1851762
• Languages: English
• ISSNs: 2168-1805

Abstract

Abstract: Objective: To investigate time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer in Sweden, and the associated health economic impact. Materials and methods: Registry study (NCT03619980) of the Prostate Cancer data Base Sweden with data from the National Prostate Cancer Register, including the Patient-overview Prostate Cancer (PPC) and other national healthcare registries. The primary endpoint was time in each disease state. Secondary endpoints were co-medications, comorbidities and healthcare resource utilization (HRU) and cost in each disease state. Results: In total, 1, 869 men with advanced prostate cancer registered in PPC between 2014 and 2016, with data on the start of androgen deprivation therapy, were identified. Median time to progression and median survival were 4 and 11 years, respectively, for men with non-metastatic (nm) hormone-sensitive prostate cancer (HSPC); 1 and 7 years for men with metastatic (m) HSPC; and 1 and 8.5 years for men with nm castration-resistant prostate cancer (CRPC). Median survival for men with mCRPC was 4 years. Total annual mean costs for HRU per patient increased with increasing severity of disease, from 41, 064 Swedish krona (SEK) for nmHSPC to 288, 242 SEK for mCRPC. Conclusion: Progression time from mHSPC and nmCRPC to the mCRPC state was short and survival in the mCRPC state was approximately 4 years. Survival times were longer than expected, likely due to the selection of long-term survivors among prevalent cases. Healthcare costs were high for men with mCRPC. Further studies are needed to confirm our pilot study findings.